LAB STANDARD BIOTOOLS INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1162194 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-2.2%
TTM net income YoY203.8%
TTM EPS YoY203.0%
Revenue 3-yr CAGR-7.1%
Net income 3-yr CAGR—
Margins
Gross margin52.2%
Operating margin-97.5%
Net margin157.6%
FCF margin-77.8%
EBITDA margin-91.3%
Returns
ROE27.9%
ROA22.7%
ROIC (approx.)-23.4%
Asset turnover0.14x
Leverage & solvency
Liabilities / assets12.5%
Debt / equity0.00x
Current ratio9.75x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.48x
Accruals ratio33.6%
Payout ratio—
Capex / revenue1.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $85.33M | $91.01M |
| Cost of revenue | $42.79M | $46.12M |
| Gross profit | $42.54M | $44.88M |
| R&D expense | $25.99M | $28.83M |
| SG&A expense | $109.86M | $103.06M |
| Operating income | -$110.25M | -$127.48M |
| Pretax income | -$96.70M | -$90.40M |
| Income tax | -$37.88M | $542,000 |
| Net income | -$74.90M | -$138.88M |
| EBITDA | -$100.99M | -$114.97M |
| EPS (basic) | -0.20 | -0.52 |
| EPS (diluted) | -0.20 | -0.52 |
| Weighted avg. shares (diluted) | 381.62M | 353.25M |
| Balance sheet | ||
| Cash & equivalents | $120.86M | $168.82M |
| Short-term investments | $66.71M | $126.15M |
| Receivables | $13.43M | $14.74M |
| Inventory | $19.98M | $20.74M |
| Current assets | $454.26M | $375.88M |
| PP&E, net | $19.27M | $22.77M |
| Goodwill | — | $111.30M |
| Intangibles | — | $28.95M |
| Total assets | $567.75M | $612.35M |
| Current liabilities | $108.31M | $65.89M |
| Long-term debt | — | $299,000 |
| Total debt | — | $299,000 |
| Total liabilities | $143.46M | $140.62M |
| Shareholders' equity | $424.29M | $471.72M |
| Net debt | — | -$168.52M |
| Shares outstanding | 386.38M | 377.53M |
| Cash flow statement | ||
| Operating cash flow | -$74.34M | -$143.45M |
| Capital expenditure | $8.30M | $8.36M |
| Free cash flow | -$82.65M | -$151.81M |
| Investing cash flow | $27.41M | $363.17M |
| Financing cash flow | $570,000 | -$102.62M |
| Depreciation & amortization | $9.26M | $12.52M |
| Stock-based compensation | $29.61M | $31.73M |
| Share buybacks | $0 | $40.49M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.